The clinicopathological significances and related signal pathways of BTG3 mRNA expression in cancers: A bioinformatics analysis.

B cell transposition gene 3 (BTG3) is reported to be a tumor suppressor and suppresses proliferation and cell cycle progression. This study aims to analyze the clinicopathological and prognostic significances, and signal pathways of mRNA expression in human beings through bioinformatics analysis. We analyzed expression using Oncomine, TCGA (the cancer genome atlas), Xiantao, UALCAN (The University of ALabama at Birmingham Cancer data analysis Portal) and Kaplan-Meier plotter databases. Down-regulated expression was observed in lung and breast cancers, compared with normal tissues ( < 0.05), but not for gastric and ovarian cancer ( < 0.05). The methylation of was shown to be adversely correlated with its mRNA expression ( < 0.05). expression was higher in gastric intestinal-type than diffuse-type carcinomas, G than G carcinomas ( < 0.05), in female than male cancer patients, T than T, and adenocarcinoma than squamous cell carcinoma of lung cancer ( < 0.05), in invasive ductal than lobular carcinoma, N than N and N, TNBC (triple-negative breast cancer) than luminal and Her2+, and Her2+ than luminal cancer of breast cancer ( < 0.05), and G than G ovarian carcinoma ( < 0.05). expression was positively related to the survival rate of gastric and ovarian cancer patients ( < 0.05), but not for breast cancer ( < 0.05). KEGG and PPI (protein-protein interaction) analysis showed that the was involved in cell cycle and DNA replication, digestion and absorption of fat and protein, spliceosome and ribosome in cancer. expression was positively linked to carcinogenesis, histogenesis, and aggressive behaviors, and was employed to evaluate the prognosis of cancers by regulating cell cycle, metabolism, splicing and translation of RNA.